C4 Therapeutics, Inc.CCCCEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 9.90% | 6.9M | ▲ +3.50pp | 2024-11-14 |
| NOS. OF ABOVE PERSONS | 9.40% | 6.6M | ▲ +4.20pp | 2024-11-14 |
| Betta Investment | 8.10% | 5.6M | — | 2024-01-12 |
| Wasatch Advisors LP | 8.00% | — | ▼ -6.50pp | 2024-03-08 |
| BlackRock, Inc. | 7.10% | 4.9M | flat | 2024-11-08 |
| Commodore | 4.80% | 3.4M | — | 2024-11-14 |
| STATE STREET CORPORATION | 4.35% | 12.5K | ▼ -6.08pp | 2024-07-10 |
| OrbiMed Advisors LLC | 2.10% | 1.5K | — | 2024-11-14 |
| Point72 Asset Management, L.P. | 1.90% | 1.3M | ▼ -2.80pp | 2024-11-14 |
| T. ROWE PRICE ASSOCIATES, INC. | 0.60% | 392.0K | ▼ -4.60pp | 2024-11-14 |
| RTW Investments, LP | 0.00% | 12.5K | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | GROGAN DONNA ROY | Director | Grant | 5.4K | $2.70 | $14.5K |
| 2026-04-01 | Anderson Kenneth Carl | Director | Grant | 4.3K | $2.70 | $11.5K |
| 2026-02-15 | Andrew Hirsch | President & CEO | Option exercise | 20.4K | $0.00 | $0 |
| 2026-02-14 | Kelly Schick | Chief People Officer | Option exercise | 20.9K | $0.00 | $0 |
| 2026-02-14 | Paige Mahaney | Chief Scientific Officer | Option exercise | 7.0K | $0.00 | $0 |
| 2026-02-14 | Andrew Hirsch | President & CEO | Option exercise | 81.7K | $0.00 | $0 |
| 2026-02-14 | Boyle Scott N | Chief Business Officer | Option exercise | 20.9K | $0.00 | $0 |
| 2026-02-14 | Kendra Adams | Chief Financial Officer | Option exercise | 30.9K | $0.00 | $0 |
| 2026-02-14 | REYNO LEONARD | Chief Medical Officer | Option exercise | 30.9K | $0.00 | $0 |
| 2026-02-14 | Mark Mossler | Chief Accounting Officer | Option exercise | 9.4K | $0.00 | $0 |
1–10 of 20
Page 1 / 2